博雅生物
(300294)
| 流通市值：74.23亿 | | | 总市值：74.23亿 |
| 流通股本：5.04亿 | | | 总股本：5.04亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 643,555,888.03 | 321,128,375.86 | 2,059,088,027.17 | 1,473,924,123.26 |
| 营业收入 | 643,555,888.03 | 321,128,375.86 | 2,059,088,027.17 | 1,473,924,123.26 |
| 二、营业总成本 | 614,673,835.61 | 296,220,781.81 | 1,738,837,657.08 | 1,228,094,382.4 |
| 营业成本 | 359,063,537.9 | 172,563,810.33 | 1,031,721,835.18 | 675,003,264.47 |
| 税金及附加 | 10,002,055.49 | 5,071,317.57 | 19,374,755.99 | 14,546,433.13 |
| 销售费用 | 148,184,047.08 | 73,703,551.86 | 412,671,829.14 | 293,128,543.42 |
| 管理费用 | 103,289,144.66 | 50,714,378.77 | 239,178,310.56 | 220,993,490.91 |
| 研发费用 | 11,990,387.43 | 4,235,819.09 | 54,554,236.59 | 36,855,903.92 |
| 财务费用 | -17,855,336.95 | -10,068,095.81 | -18,663,310.38 | -12,433,253.45 |
| 其中:利息费用 | 1,247,412.3 | 631,044.98 | 1,161,725.54 | 662,641.05 |
| 其中:利息收入 | 8,339,954.6 | 4,073,006.41 | 13,615,107.1 | 10,483,522.99 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 10,444,438.13 | 6,725,948.97 | 59,977,597.95 | 48,373,036.29 |
| 加:投资收益 | -34,436,670.69 | 3,933,274.5 | 23,806,314.16 | 24,863,589.47 |
| 资产处置收益 | -394,883.47 | -348,365.67 | 5,095,324.42 | 5,027,740.43 |
| 资产减值损失(新) | -156,560.68 | -155,939.71 | -316,529,570.79 | -660,409.3 |
| 信用减值损失(新) | -4,720,502.68 | -1,582,061.29 | -23,652,590.17 | -11,413,863.29 |
| 其他收益 | 5,842,568.1 | 3,667,173.74 | 40,474,982.72 | 30,325,474.03 |
| 四、营业利润 | 5,460,441.13 | 37,147,624.59 | 109,422,428.38 | 342,345,308.49 |
| 加:营业外收入 | 683,778.51 | 143,120.15 | 3,023,017.98 | 2,660,249.67 |
| 减:营业外支出 | 2,718,184.21 | 1,287,236.19 | 8,566,951.28 | 3,670,806.65 |
| 五、利润总额 | 3,426,035.43 | 36,003,508.55 | 103,878,495.08 | 341,334,751.51 |
| 减:所得税费用 | -47,458,848.1 | 5,970,116.3 | -8,760,276.94 | -1,708,206.1 |
| 六、净利润 | 50,884,883.53 | 30,033,392.25 | 112,638,772.02 | 343,042,957.61 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 23,989,528.83 | 30,033,392.25 | 112,638,772.02 | 343,042,957.61 |
| 终止经营净利润 | 26,895,354.7 | - | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 51,188,692.08 | 30,220,896.06 | 112,698,348.56 | 342,961,782.6 |
| 少数股东损益 | -303,808.55 | -187,503.81 | -59,576.54 | 81,175.01 |
| 扣除非经常损益后的净利润 | 17,151,386.51 | 20,323,474.32 | -7,757,477.26 | 209,904,556.55 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.06 | 0.22 | 0.68 |
| (二)稀释每股收益 | 0.1 | 0.06 | 0.22 | 0.68 |
| 八、其他综合收益 | -10,184,885.93 | -5,943,787.21 | -5,885,761.41 | -3,039,859.77 |
| 归属于母公司股东的其他综合收益 | -10,184,885.93 | -5,943,787.21 | -5,885,761.41 | -3,039,859.77 |
| 九、综合收益总额 | 40,699,997.6 | 24,089,605.04 | 106,753,010.61 | 340,003,097.84 |
| 归属于母公司股东的综合收益总额 | 41,003,806.15 | 24,277,108.85 | 106,812,587.15 | 339,921,922.83 |
| 归属于少数股东的综合收益总额 | -303,808.55 | -187,503.81 | -59,576.54 | 81,175.01 |
| 公告日期 | 2026-08-22 | 2026-04-25 | 2026-03-21 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |